GLP-1 & Incretin Science

Why -41.7 and -4.5 Are the Same Size

UKPWritten and published by UK Peptides4 min readUpdated 4 cited sources

The short answer

The WOMAC pain subscale has five items and is reported either on a 0-20 Likert scale or normalised to 0-100. Two major incretin osteoarthritis trials used different versions, so their published point changes differ by a factor of five before any biology is involved.

Key facts

Instrument
Western Ontario and McMaster Universities Osteoarthritis Index
Pain subscale items
5
Likert scoring
0-4 per item, 0-20 total
Normalised scoring
0-100
Direction
Higher score = worse pain
STEP 9 version used
0-100, mean baseline 70.9
TRIUMPH-4 version used
0-20, mean baseline 6.0
Other subscales
Stiffness (2 items), physical function (17 items)

What the five items are

The pain subscale asks about pain in five specific situations, each scored on a five-point scale from none to extreme. Knowing the items matters, because it tells you what the instrument can and cannot register.

  • Walking on flat ground
  • Going up or down stairs
  • At night while in bed
  • Sitting or lying
  • Standing upright

The two scoring conventions, and the confusion they cause

On the Likert version each item scores 0 to 4, giving a subscale range of 0 to 20. Many trials instead normalise to 0 to 100. Both are 'the WOMAC pain score' and both are correctly described that way in a paper. The problem arises when results from trials using different conventions are quoted side by side, as happened with the two large incretin osteoarthritis trials. STEP 9 reported semaglutide on the 0-100 scale: mean baseline 70.9, change -41.7 points with semaglutide and -27.5 with placebo. TRIUMPH-4 reported retatrutide on the 0-20 Likert scale: mean baseline 6.0, change -4.5 and -4.4 points on the two active arms and -2.4 on placebo.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why the raw comparison is wrong twice over

Line up -41.7 and -4.5 and semaglutide appears to have relieved pain roughly nine times more effectively. It did not. The first correction is the scale: a factor of five separates 0-100 from 0-20, so -4.5 on the Likert scale corresponds to about -22.5 on the normalised scale. The second correction is the baseline, and it is larger than the first. STEP 9 required at least moderate pain and enrolled a population averaging 70.9 out of 100. TRIUMPH-4 set entry criteria on pain duration and frequency (more than 12 weeks, on more than 15 days of the previous month) plus Kellgren-Lawrence grade 2 or 3 radiographic change, with no pain-severity threshold, and enrolled a population averaging 6.0 out of 20, which is 30 out of 100. The two trials studied populations with roughly twice the difference in baseline pain, and a scale can only fall as far as its floor allows.

Relative change is the least bad common currency

Expressing each result as a percentage of its own baseline removes both problems at once, though not perfectly. On that basis STEP 9's semaglutide arm improved 58.8% and its placebo arm 38.8%; TRIUMPH-4's retatrutide arms improved 75.8% and 74.3% and its placebo arm 40.3%. The residual distortion is that floor effects bite harder at low baselines (it is easier to lose 75% of 6 points than 75% of 70.9), so relative change flatters the milder population. It is still far better than comparing raw point changes, which is an error rather than an approximation.

The placebo response is the most reproducible number here

The single most striking thing in that paragraph is easy to miss: the two placebo arms improved by 38.8% and 40.3% of their own baselines, in different populations, on different scales, in trials run by different sponsors on different continents years apart. Osteoarthritis pain trials produce large and remarkably consistent placebo responses, driven by regression to the mean, the natural fluctuation of osteoarthritis symptoms, the attention and structure of trial participation, and the well-documented responsiveness of self-reported pain to expectation. Any pain trial without a randomised control arm is close to uninterpretable, and any single-arm pain claim should be read against a 40% expectation.

What counts as a meaningful change

Thresholds for minimal clinically important difference in WOMAC vary by population, by version and by how they were derived, and no single number applies everywhere. A commonly used rule of thumb treats a change of around 10% of the scale as the smallest that a person is likely to perceive, with higher thresholds where the question is whether an intervention justified a major procedure. The general point is more useful than any specific number: a statistically significant change on a patient-reported scale is not automatically a change a person would notice, and the two questions have to be asked separately.

Quick reference

STEP 9 (semaglutide)TRIUMPH-4 (retatrutide)
RegistrationNCT05064735NCT05931367
Participants407445
Duration68 weeks68 weeks
WOMAC pain scale used0-1000-20 Likert
Mean baseline pain70.96.0 (= 30 on 0-100)
Active arm change-41.7 points (-58.8%)-4.5 points (-75.8%)
Placebo change-27.5 points (-38.8%)-2.4 points (-40.3%)
Body weight, active arm-13.7%-26.4% to -28.7%

Frequently asked questions

Which WOMAC version is correct?

Both. They are the same instrument reported on different scales, and each paper states which it used. The error is not in the trials but in comparisons that ignore the statement.

Does a bigger WOMAC change mean better pain relief?

Only within the same trial, on the same scale, against the same control. Across trials it means almost nothing without adjusting for scale and baseline, and even then the populations differ in ways no adjustment fixes.

Why do osteoarthritis trials have such large placebo responses?

Because osteoarthritis pain fluctuates naturally, people enrol when it is bad, so regression to the mean pulls scores down regardless of treatment. Self-reported pain is also sensitive to expectation and to the structured attention of trial participation. The effect is consistent enough to be a design assumption rather than a surprise.

Is WOMAC a measure of joint damage?

No. It is entirely patient-reported and covers pain, stiffness and physical function. It records what a person experiences, which is the outcome that matters to them, but it says nothing directly about cartilage, and structural and symptomatic endpoints can move independently.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.